Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Alosaimy, Sara, Jorgensen, Sarah C J, Lagnf, Abdalhamid M, Melvin, Sarah, Mynatt, Ryan P, Carlson, Travis J, Garey, Kevin W, Allen, David, Venugopalan, Veena, Veve, Michael, Athans, Vasilios, Saw, Stephen, Yost, Christine N, Davis, Susan L, Rybak, Michael J
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Brief Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7060146/
https://ncbi.nlm.nih.gov/pubmed/32161775
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofaa051
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars